Compare Becton Dickinson and Co (BDX) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs VanEck Rare Earth/Strategic Metals — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while VanEck Rare Earth/Strategic Metals trades at $77.91. The key difference: Becton Dickinson and Co pays a 2.79% dividend while VanEck Rare Earth/Strategic Metals pays none, and VanEck Rare Earth/Strategic Metals is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | REMX | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.39 | $109.53 |
52-Week Low | $135.49 | $47.36 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $76.27, down 4.38% today amid bearish technical signals. The ETF faces high volatility (~50% annualized) and significant China concentration risk, though recent news highlights growing institutional interest in rare earths as critical for AI and defense infrastructure. Technical indicators show oversold RSI readings but dominant bearish moving average signals.
Outlook remains speculative given geopolitical supply chain dependencies and commodity price sensitivity. Investment appeal hinges on long-term rare earth demand growth from technology and energy transitions, but risks include China export controls and ETF liquidity constraints. Current levels near support at $76 may attract tactical buyers despite near-term bearish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
